PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmcpsycBioMed Centralsearchsubmit a manuscriptregisterthis articleBMC Psychiatry
 
BMC Psychiatry. 2012; 12: 25.
Published online Mar 26, 2012. doi:  10.1186/1471-244X-12-25
PMCID: PMC3361492
Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database
Tim Lambert,corresponding author1,2 Brett Emmerson,3 Harry Hustig,4 Sophie Resseler,5 An Jacobs,6 and Belinda Butcher7,8, the e-STAR Research Group
1Department of Psychiatry, The University of Melbourne, Melbourne, Australia
2Concord Medical School and Brain and Mind Research Institute, University of Sydney, Camperdown, NSW, Australia
3Mental Health Services, Royal Brisbane and Women's Hospital, Herston, QLD, Australia
4Extended Care Services, Royal Adelaide Hospital, North Terrace Adelaide, SA, Australia
5Life Science Services--Biometrics, SGS, Antwerp, Belgium
6Health Economics & Pricing, Janssen Pharmaceutica, Beerse, Belgium
7Medical Research, Janssen-Cilag Pty Ltd, North Ryde, NSW, Australia
8WriteSource Medical Pty Ltd, Lane Cove, NSW, Australia
corresponding authorCorresponding author.
Tim Lambert: tim.lambert/at/sydney.edu.au; Brett Emmerson: Brett_Emmerson/at/health.qld.gov.au; Harry Hustig: Harry.Hustig/at/health.sa.gov.au; Sophie Resseler: Sophie.resseler/at/sgs.com; An Jacobs: AJACOBS/at/its.jnj.com; Belinda Butcher: bbutcher/at/writesourcemedical.com.au
Received July 13, 2011; Accepted March 26, 2012.
Abstract
Background
This observational study was designed to collect treatment outcomes data in patients using the electronic Schizophrenia Treatment Adherence Registry (e-STAR).
Methods
Patients with schizophrenia or schizoaffective disorder in Australia who were prescribed risperidone long-acting injection (RLAI) between 2003 and 2007 were assessed 12-months retrospectively, at baseline and 24-months prospectively at 3-monthly intervals. The intent-to-treat population, defined as all patients who received at least one dose of RLAI at baseline, was used for the efficacy and safety analyses.
Results
At total of 784 patients (74% with schizophrenia, 69.8% male) with a mean age of 37.1 ± 12.5 years and 10.6 ± 9.5 years since diagnosis were included in this Australian cohort. A significant improvement in mean Clinical Global Impression - severity score was observed at 24-months (4.52 ± 1.04 at baseline, 3.56 ± 1.10 at 24-months). Most of this improvement was seen by 3-months and was also reflected in mean Global Assessment of Functioning score, which improved significantly at 24-months (42.9 ± 14.5 at baseline, 59 ± 15.4 at 24-months). For patients still receiving RLAI at 24-months there was an increase from a mean baseline RLAI dose of 26.4 ± 5 mg to 43.4 ± 15.7 mg. Sixty-six percent of patients discontinued RLAI before the 24-month period--this decreased to 46% once patients lost to follow-up were excluded.
Conclusion
Over the 24-month period, initiation of RLAI was associated with improved patient functioning and illness severity in patients with schizophrenia or schizoaffective disorder. Improved outcomes were observed early and sustained throughout the study.
Trial Registration
Clinical Trials Registration Number, NCT00283517.
Articles from BMC Psychiatry are provided here courtesy of
BioMed Central